Pharma Pioneer

Rani Therapeutics Reports Positive Phase 1 Results for Oral Anti-IL 12/23 Antibody (RT-111)

31 May 2024
2 min read

Feb. 05, 2024 – Rani Therapeutics Holdings, Inc. reported encouraging topline results from its Phase 1 clinical trial of RT-111, a RaniPill® capsule containing an ustekinumab biosimilar (CT-P43). RT-111 was well-tolerated, with no serious adverse events, and achieved high bioavailability.

Key Highlights:

RT-111 delivered ustekinumab in a dose-proportional manner with an estimated 84% bioavailability relative to subcutaneous injection.
The study demonstrated higher peak concentration (Cmax) and shorter time to reach peak concentration (Tmax) compared to subcutaneous administration.
RT-111 was well-tolerated with no serious adverse events. Participants did not report difficulty swallowing the capsule, and capsule remnants passed without issues.
The Phase 1 study, conducted in Australia, included 20 participants each in the RT-111 0.5mg and 0.75mg dose groups, and 15 participants in a 0.5mg subcutaneous ustekinumab injection group. The results confirmed the clinical potential of RT-111 as an oral alternative to injectable biologics for patients with autoimmune conditions, offering a less burdensome dosing regimen.

Rani Therapeutics has now successfully completed three Phase 1 trials using its RaniPill® technology, marking significant progress towards developing oral biologics.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Triumvira Begins Phase I/II Trial for TAC101-CLDN18.2 Solid Tumor Therapy
Pharma Pioneer
3 min read
Triumvira Begins Phase I/II Trial for TAC101-CLDN18.2 Solid Tumor Therapy
31 May 2024
This study is focused on evaluating the safety and effectiveness of TAC101-CLDN18.2, an advanced cell therapy that utilizes genetically modified autologous T cells.
Read →
Neuroinflammation: Alzheimer's Promising Treatment Target
Pharma Pioneer
3 min read
Neuroinflammation: Alzheimer's Promising Treatment Target
31 May 2024
In the early 20th century, Alois Alzheimer identified neuroinflammation as a factor in the disease now named after him, noting the presence of microglia cells in his initial sketches.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 30
Pharma Frontiers
12 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 30
30 May 2024
May 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
TILT Biotherapeutics Shares Clinical Results of TILT-123 for Ovarian Cancer at ASCO 2024
Latest Hotspot
3 min read
TILT Biotherapeutics Shares Clinical Results of TILT-123 for Ovarian Cancer at ASCO 2024
30 May 2024
TILT Biotherapeutics' one abstract highlights encouraging safety and efficacy findings of TILT-123 in patients with ovarian cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.